Recon: FDA allowing some reviewers to telework; Trump threatens tariffs on prescription drugs

• The trade war hits pause, but the biotech doom loop carries on (STAT)
• FDA reverses course on telework after layoffs and resignations threaten basic operations (Associated Press)
• Biotech CEOs to Cassidy: We're already seeing the effects of FDA's staff cuts (Endpoints)
• Medtech Looks For Relief As Trump Hits Pause On Most Tariffs (MedTech Insight)
• Prescription drugs become a target in Trump's trade war (Reuters)
• Trump administration plans to remove all members of HIV advisory council (Reuters)
• US measles battle hindered by confusion over health secretary response (Reuters)

• DHL pours €2B into healthcare logistics; OXB revenues on the rise (Endpoints)
• EU Harmonized Standards Continue To Trickle In Under MDR (MedTech Insight)
• Medtechs Eye German Health Minister Switch As Governing Parties Reach Coalition Agreement (MedTech Insight)
• Major Analysis To Help MHRA Fill Gaps In UK Clinical Trials Landscape (Pink Sheet)

• Gilead is urged to rework licensing deals for groundbreaking HIV prevention drug (STAT)
• Alzheon’s amyloid-targeting pill fails another Phase 3 study in Alzheimer’s (Endpoints)
• J&J, argenx keep rolling out myasthenia gravis data, plus more from #AAN25 (Endpoints)
• PacBio to cut jobs, lower spending over NIH funding cuts and tariffs (Reuters)
• Tempest seeks strategic alternatives to fund Phase 3 liver cancer trial (Endpoints)
• Exclusive: Cardiometabolic biotech gets $57.5M Series B, with help from Cytokinetics (Endpoints)
• Keros Therapeutics adopts poison pill as it explores options, including sale (Reuters)

• AI agents in health care: Everything you need to know, but didn’t know how to ask (STAT)
• Therapy AI chatbot shows promising results: study (Endpoints)
• Teleflex to close Minnesota facility, cut 101 employees (MedTech Dive)
• AI scribe technology lets me focus on my patients, not a screen (STAT)
• Kandu Health merges with BCI company Neurolutions (MedTech Dive)
• ‘Preparing For Regulatory Milestones, Commercial Launch’ Are Priorities, Says New Freenome CEO Aaron Elliott (MedTech Insight)

• The wellness industry is killing animals, spreading disease, and fueling the next pandemic (STAT)
• Debate over soda, candy bans shows how MAHA is scrambling old alliances (STAT)
• Tariffs are the latest test of beleaguered US consumers (Food Dive)
• Using RASFF Data, Researchers Develop Integrated AI Framework for Improved Food Safety Risk Assessment (Food Safety)

• The National Cancer Institute’s Investigational New Drug program is imperative for public good (STAT)
• US NIH scientists barred from attending conferences on their own time and dime (Reuters)
• National public health group calls for RFK Jr. to resign, citing ‘complete disregard for science’ (STAT)
• NIH cancels funding for landmark diabetes study at a time of focus on chronic disease (STAT)
• On an RFK Jr. road show, MAHA goals take precedence. Measles prevention less so (STAT)
• USDA to lose bird flu response employees, source says (Reuters)
• More on the Impact of the FDA RIFs: How Information Disclosure will Start FOIA-lling Behind (FDA Law Blog)